Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
6
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
biotech
deals
pfizer
startups
abbvie
cancer
cancer immunotherapy
eli lilly
gilead sciences
medicare
novartis
bristol-myers squibb
What
bio
drug
6
×
roundup
6
×
alzheimer’s
week
acquisitions
biggest
biogen’s
ceo
companies
nash
news
price
prices
aducanumab
albert
amyloid
angst
annual
approval
assessed
attention
bagged
billions
biogen
biopharmaceutical
biotech
bourla
brammer
build
buy
communities
company
company’s
conference
convo
crispr
daniel
debut
different
Language
unknown
unset
Current search:
roundup
×
drug
×
" detroit blog main "
×
" alzheimer's disease "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More